Call +1 858 457-8383 Fax +1 858 457-8484

Concanamycin B (high purity)

BVT-0253-C025 25 µg $80.00
BVT-0253-C100 100 µg $150.00
BVT-0253-C500 500 µg $450.00
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +1 858 457-8383
Fax +1 858 457-8484
Contact Us!

Additional Information

Product Data
Synonyms 8-Deethyl-8-methylconcanamycin A
Properties
Formula C45H73NO14
MW 852.1
CAS 81552-33-2
Source/Host Chemicals Isolated from Streptomyces sp.
Purity ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO, chloroform, acetonitrile or methanol; insoluble in water.
Identity Determined by 1H-NMR.
Origin Manufactured by BioViotica.
InChi Key AQXXGIBOZQZSAT-UZYXLCJWSA-N
Product Type Chemical
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C.
Documents
MSDS Download Document Download
Related Products

Product Description

  • Antibiotic.
  • Exhibits similar activity as concanamycin A (Prod. No. BVT-0237) and concanamycin C (Prod. No. BVT-0254).
  • Specific vacuolar-type H+-ATPase inhibitor.
  • Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases.
  • Suppresses bone resorption.
  • Inhibits proliferation of mouse splenic lymphocytes.
  • Antifungal and larvicidal.

Product References

  1. Structures of concanamycins B and C: H. Kinashi, et al.; J. Antibiot. 35, 1618 (1982)
  2. Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. (Tokyo) 37, 1333 (1984)
  3. Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268, 19092 (1993)
  4. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosintriphosphatase: S. Drose, et al.; Biochemistry 32, 3902 (1993)
  5. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2), 381 (1995)
  6. Concanamycin B inhibits the expression of newly synthesized MHC class II molecules on the cell surface: K. Ito, et al.; J. Antibiot. 48, 488 (1995)
  7. Concanamycin B, a vacuolar H(+)-ATPase specific inhibitor suppresses bone resorption in vitro: J.T. Woo, et al.; Biol. Pharm. Bull. 19, 297 (1996)
  8. In vivo rapid reduction of alloantigen-activated CD8+ mature cytotoxic T cells by inhibitors of acidification of intracellular organelles, prodigiosin 25-C and concanamycin B: M. H. Lee, et al.; Immunology 99, 243 (2000)
  9. Vacuolar H+-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway: Y. Sasazawa, et. al.; Cancer Sci. 100, 1460 (2009)
  10. Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins: J. A. Sobota, et. al.; J. Cell Sci. 122, 3542 (2009)
  11. Inhibitors of V-ATPase: old and new players: M. Huss, et. al.; J. Exp. Biol. 212, 341 (2009)
No reviews for this product yet.